From: NRESCommittee.EastMidlands-Nottingham2@nhs.net <noreply@harp.org.uk>

Sent: 24 October 2019 12:18

To: Nikola Sprigg <mszns4@exmail.nottingham.ac.uk>; Nikola Sprigg <mszns4@exmail.nottingham.ac.uk>;

sponsor@nottingham.ac.uk **Cc:** nhsg.nrspcc@nhs.net

Subject: IRAS PROJECT ID 233744, REC Reference 18/EM/0184 Confirmation of favourable opinion for

substantial amendment

#### Dear Dr Sprigg

IRAS project ID:	233744
REC reference:	18/EM/0184
Short Study title:	Desmopressin for treatment of stroke patients on antiplatelet therapy
Date complete amendment submission received:	16 September 2019
Amendment No./ Sponsor Ref:	SA/03/19
Amendment Date:	13 September 2019
Amendment Type:	Substantial
Outcome of HRA Assessment	This email also constitutes HRA and HCRW Approval for the amendment, and you should not expect anything further.

I am pleased to confirm that this amendment has been reviewed by the Research Ethics Committee and has received a Favourable Opinion. Please find attached a copy of the Favourable Opinion letter.

### **HRA and HCRW Approval Status**

As detailed above, this email also constitutes HRA and HCRW Approval for the amendment. No separate notice of HRA and HCRW Approval will be issued. You should implement this amendment at NHS organisations in England and/or Wales, in line with the conditions outlined in your categorisation email.

- If this study has HRA and HCRW Approval, this amendment may be implemented at participating NHS organisations in England and/or Wales once the conditions detailed in the categorisation section above have been met
- If this study is a pre-HRA Approval study, this amendment may be implemented at
  participating NHS organisations in England and/or Wales that have NHS Permission, once
  the conditions detailed in the categorisation section above have been met. For participating
  NHS organisations in England and/or Wales that do not have NHS Permission, these sites
  should be covered by HRA and HCRW Approval before the amendment is implemented at
  them, please see below;
- If this study is awaiting HRA and HCRW Approval, I have passed your amendment to my colleague and you should receive separate notification that the study has received HRA and HCRW Approval, incorporating approval for this amendment.

### **User Feedback**

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <a href="http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/">http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/</a>.

If you require further information, please contact <a href="mailto:hra.amendments@nhs.net">hra.amendments@nhs.net</a>

# 18/EM/0184/AM05 Please quote this number on all correspondence

Kind regards

## **Joanne O'Neil**

**Approvals Administrator** 

**Health Research Authority** 

The Old Chapel | Royal Standard Place | Nottingham HRA1 Meeting Room | NG1 6FS

T. 0207 104 8108

E. NRESCommittee.EastMidlands-Nottingham2@nhs.net

W. www.hra.nhs.uk

Sign up to receive our newsletter HRA Latest.